EGFR and lung cancer: Interestingly, KPT-185 equally inhibited the viability of EGFR-TKI-resistant H1975 and H1650GR cells and EGFR-TKI-sensitive HCC827 cells, indicating that KPT-185 may be a good candidate for the effective control of EGFR-TKI-resistant lung cancers.